Brief: Adocia Announces Positive Topline Results For First Clinical Study Of Biochaperone® Pramlintide Insulin

Adocia SA

05/09/2018 17:12

Sept 5 (Reuters) - Adocia SA  ADOC.PA :
    * ADOCIA ANNOUNCES POSITIVE TOPLINE RESULTS FOR THE FIRST
CLINICAL
STUDY OF BIOCHAPERONE® PRAMLINTIDE INSULIN IN PEOPLE WITH TYPE 1
DIABETES
    * BIOCHAPERONE(®) PRAMLINTIDE INSULIN IS FIRST PRODUCT TO
CLINICALLY DEMONSTRATE FEASIBILITY OF A FIXED-RATIO
CO-FORMULATION OF PRAMLINTIDE AND HUMAN INSULIN
    * BC PRAM INS SHOWED A SIGNIFICANT 97% DECREASE IN BLOOD
GLUCOSE
EXCURSION OVER FIRST TWO HOURS AFTER MEAL COMPARED TO HUMALOG(®)
    * BC PRAM INS SHOWED SIMILAR GLUCOSE CONTROL OVER FIRST TWO
HOURS
AFTER MEAL COMPARED TO SEPARATE INJECTIONS OF SYMLIN(®) AND
HUMULIN(®)
    * ALL TREATMENTS WERE WELL TOLERATED

Source text for Eikon:  ID:nBw82CdMTa 
Further company coverage:  ADOC.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))